Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression

Abstract

Beside the well-known deficiency in serotonergic neurotransmission as pathophysiological correlate of major depression (MD), recent evidence points to a pivotal role of increased glutamate receptor activation as well. However, cause and interaction of these neurotransmitter alterations are not understood. In this review, we present a hypothesis integrating current concepts of neurotransmission and hypothalamus–pituitary–adrenal (HPA) axis dysregulation with findings on immunological alterations and alterations in brain morphology in MD. An immune activation including increased production of proinflammatory cytokines has repeatedly been described in MD. Proinflammatory cytokines such as interleukin-2, interferon-γ, or tumor necrosis factor-α activate the tryptophan- and serotonin-degrading enzyme indoleamine 2,3-dioxygenase (IDO). Depressive states during inflammatory somatic disorders are also associated with increased proinflammatory cytokines and increased consumption of tryptophan via activation of IDO. An enhanced consumption of serotonin and its precursor tryptophan through IDO activation could well explain the reduced availability of serotonergic neurotransmission in MD. An increased activation of IDO and its subsequent enzyme kynurenine monooxygenase by proinflammatory cytokines, moreover, leads to an enhanced production of quinolinic acid, a strong agonist of the glutamatergic N-methyl-D-aspartate receptor. In inflammatory states of the central nervous system, IDO is mainly activated in microglial cells, which preferentially metabolize tryptophan to the NMDA receptor agonist quinolinic acid, whereas astrocytes – counteracting this metabolism due to the lack of an enzyme of this metabolism – have been observed to be reduced in MD. Therefore the type 1/type 2 immune response imbalance, associated with an astrocyte/microglia imbalance, leads to serotonergic deficiency and glutamatergic overproduction. Astrocytes are further strongly involved in re-uptake and metabolic conversion of glutamate. The reduced number of astrocytes could contribute to both, a diminished counterregulation of IDO activity in microglia and an altered glutamatergic neurotransmission. Further search for antidepressant agents should take into account anti-inflammatory drugs, for example, cyclooxygenase-2 inhibitors, might exert antidepressant effects by acting on serotonergic deficiency, glutamatergic hyperfunction and antagonizing neurotoxic effects of quinolinic acid.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Matussek N . Neurobiologie und depression. Med Monatsschr 1966; 3: 109–112.

    Google Scholar 

  2. Coppen A, Swade C . 5-HT and depression: the present position. In: Briley M, Fillion G (eds). New Concepts in Depression. MacMillan Press: London, 1988, pp 120–136.

    Google Scholar 

  3. Crane GE . Cyloserine as an antidepressant agent. Am J Psychiatry 1959; 115: 1025–1026.

    Article  CAS  PubMed  Google Scholar 

  4. Maj J, Rogoz Z, Skuza G, Sowinska H . Effects of MK-801 and antidepressant drugs in the forced swimming test in rats. Eur Neuropsychopharmacol 1992; 2: 37–41.

    Article  CAS  PubMed  Google Scholar 

  5. Trullas R, Skolnick P . Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990; 185: 1–10.

    Article  CAS  PubMed  Google Scholar 

  6. Yilmaz A, Schulz D, Aksoy A, Canbeyli R . Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav 2002; 71: 341–344.

    Article  CAS  PubMed  Google Scholar 

  7. Nestelbaum Z, Siris SG, Rifkin A, Klar H, Reardon GT . Exacerbation of schizophrenia associated with amantadine. Am J Psychiatry 1986; 143: 1170–1171.

    Article  CAS  PubMed  Google Scholar 

  8. Palucha A, Pilc A . The involvement of glutamate in the pathophysiology of depression. Drug News Perspect 2005; 18: 262–268.

    Article  CAS  PubMed  Google Scholar 

  9. Kugaya A, Sanacora G . Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr 2005; 10: 808–819.

    Article  PubMed  Google Scholar 

  10. Huber TJ, Dietrich DE, Emrich HM . Possible use of amantadine in depression. Pharmacopsychiatry 1999; 32: 47–55.

    Article  CAS  PubMed  Google Scholar 

  11. Stryjer R, Strous RD, Shaked G, Bar F, Feldman B, Kotler M et al. Amantadine as augmentation therapy in the management of treatment-resistant depression. Int Clin Psychopharmacol 2003; 18: 93–96.

    Article  PubMed  Google Scholar 

  12. Kudoh A, Takahira Y, Katagai H, Takazawa T . Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg 2002; 95: 114–118, table.

    Article  CAS  PubMed  Google Scholar 

  13. Ostroff R, Gonzales M, Sanacora G . Antidepressant effect of ketamine during ECT. Am J Psychiatry 2005; 162: 1385–1386.

    Article  PubMed  Google Scholar 

  14. Frizzo ME, Dall'Onder LP, Dalcin KB, Souza DO . Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell Mol Neurobiol 2004; 24: 123–128.

    Article  CAS  PubMed  Google Scholar 

  15. Coric V, Milanovic S, Wasylink S, Patel P, Malison R, Krystal JH . Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (Berl) 2003; 167: 219–220.

    Article  CAS  Google Scholar 

  16. Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004; 61: 705–713.

    Article  CAS  PubMed  Google Scholar 

  17. Sanacora G, Kendell SF, Fenton L, Coric V, Krystal JH . Riluzole augmentation for treatment-resistant depression. Am J Psychiatry 2004; 161: 2132.

    Article  PubMed  Google Scholar 

  18. Zarate Jr CA, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004; 161: 171–174.

    Article  PubMed  Google Scholar 

  19. Zarate Jr CA, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005; 57: 430–432.

    Article  CAS  PubMed  Google Scholar 

  20. Yan QS, Reith ME, Jobe PC, Dailey JW . Dizocilpine (MK-801) increases not only dopamine but also serotonin and norepinephrine transmissions in the nucleus accumbens as measured by microdialysis in freely moving rats. Brain Res 1997; 765: 149–158.

    Article  CAS  PubMed  Google Scholar 

  21. Martin P, Carlsson ML, Hjorth S . Systemic PCP treatment elevates brain extracellular 5-HT: a microdialysis study in awake rats. Neuroreport 1998; 9: 2985–2988.

    Article  CAS  PubMed  Google Scholar 

  22. Kim JS, Schmid-Burgk W, Claus D, Kornhuber HH . Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr 1982; 232: 299–304.

    Article  CAS  PubMed  Google Scholar 

  23. Altamura CA, Mauri MC, Ferrara A, Moro AR, D'Andrea G, Zamberlan F . Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 1993; 150: 1731–1733.

    Article  CAS  PubMed  Google Scholar 

  24. Mauri MC, Ferrara A, Boscati L, Bravin S, Zamberlan F, Alecci M et al. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 1998; 37: 124–129.

    Article  CAS  PubMed  Google Scholar 

  25. Maes M, Verkerk R, Vandoolaeghe E, Lin A, Scharpe S . Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand 1998; 97: 302–308.

    Article  CAS  PubMed  Google Scholar 

  26. Nowak G, Ordway GA, Paul IA . Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res 1995; 675: 157–164.

    Article  CAS  PubMed  Google Scholar 

  27. Nudmamud-Thanoi S, Reynolds GP . The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neurosci Lett 2004; 372: 173–177.

    Article  CAS  PubMed  Google Scholar 

  28. Scarr E, Pavey G, Sundram S, MacKinnon A, Dean B . Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder. Bipolar Disord 2003; 5: 257–264.

    Article  CAS  PubMed  Google Scholar 

  29. Martin A, Heyes MP, Salazar AM, Kampen DL, Williams J, Law WA et al. Progressive slowing of reaction time and increasing cerebrospinal fluid concentrations of quinolinic acid in HIV-infected individuals. J Neuropsychiatry Clin Neurosci 1992; 4: 270–279.

    Article  CAS  PubMed  Google Scholar 

  30. Martin A, Heyes MP, Salazar AM, Law WA, Williams J . Impaired motor skill learning, slowed reaction time, and elevated cerebrospinal fluid quinilonic acid in a sub-group of HIV-infected individuals. Neuropsychology 1993; 7: 147–149.

    Article  Google Scholar 

  31. Heyes MP, Brew BJ, Martin A, Price RW, Salazar AM, Sidtis JJ et al. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol 1991; 29: 202–209.

    Article  CAS  PubMed  Google Scholar 

  32. Heyes MP, Saito K, Lackner A, Wiley CA, Achim CL, Markey SP . Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and retrovirus-infected macaques. FASEB J 1998; 12: 881–896.

    Article  CAS  PubMed  Google Scholar 

  33. Lapin IP . Neurokynurenines (NEKY) as common neurochemical links of stress and anxiety. Adv Exp Med Biol 2003; 527: 121–125.

    Article  CAS  PubMed  Google Scholar 

  34. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M . IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005; 10: 538–544.

    Article  CAS  PubMed  Google Scholar 

  35. Myint AM, Verkerk R, Kim YK, Scharpe S, Steinbusch HW, Leonard BE . Tryptophan depletion and kynurenine pathway in depression: evidence of imbalance neuroprotection-neurodegeneration. Neuropsychopharmacology 2005; 15: 399.

    Article  CAS  Google Scholar 

  36. Fedele E, Foster AC . An evaluation of the role of extracellular amino acids in the delayed neurodegeneration induced by quinolinic acid in the rat striatum. Neuroscience 1993; 52: 911–917.

    Article  CAS  PubMed  Google Scholar 

  37. Chen Q, Surmeier DJ, Reiner A . NMDA and non-NMDA receptor-mediated excitotoxicity are potentiated in cultured striatal neurons by prior chronic depolarization. Exp Neurol 1999; 159: 283–296.

    Article  CAS  PubMed  Google Scholar 

  38. Myint AM, Kim YK . Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med Hypotheses 2003; 61: 519–525.

    Article  CAS  PubMed  Google Scholar 

  39. Weiss G, Murr C, Zoller H, Haun M, Widner B, Ludescher C et al. Modulation of neopterin formation and tryptophan degradation by Th1- and Th2-derived cytokines in human monocytic cells. Clin Exp Immunol 1999; 116: 435–440.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Braun D, Longman RS, Albert ML . A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 2005; 106: 2375–2381.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Kwidzinski E, Bunse J, Aktas O, Richter D, Mutlu L, Zipp F et al. Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J 2005; 19: 1347–1349.

    Article  CAS  PubMed  Google Scholar 

  42. Robinson CM, Hale PT, Carlin JM . The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J Interferon Cytokine Res 2005; 25: 20–30.

    Article  CAS  PubMed  Google Scholar 

  43. Carlin JM, Ozaki Y, Byrne GI, Brown RR, Borden EC . Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects. Experientia 1989; 45: 535–541.

    Article  CAS  PubMed  Google Scholar 

  44. Taylor MW, Feng GS . Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 1991; 5: 2516–2522.

    Article  CAS  PubMed  Google Scholar 

  45. Grohmann U, Fallarino F, Puccetti P . Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 2003; 24: 242–248.

    Article  CAS  PubMed  Google Scholar 

  46. Mellor AL, Munn DH . Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999; 20: 469–473.

    Article  CAS  PubMed  Google Scholar 

  47. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL . Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189: 1363–1372.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Saito K, Crowley JS, Markey SP, Heyes MP . A mechanism for increased quinolinic acid formation following acute systemic immune stimulation. J Biol Chem 1993; 268: 15496–15503.

    CAS  PubMed  Google Scholar 

  49. Alberati GD, Ricciardi CP, Kohler C, Cesura AM . Regulation of the kynurenine metabolic pathway by interferon-gamma in murine cloned macrophages and microglial cells. J Neurochem 1996; 66: 996–1004.

    Article  Google Scholar 

  50. Shimizu T, Nomiyama S, Hirata F, Hayaishi O . Indoleamine 2,3-dioxygenase. Purification and some properties. J Biol Chem 1978; 253: 4700–4706.

    CAS  PubMed  Google Scholar 

  51. Dantzer R . Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun 2001; 15: 7–24.

    Article  CAS  PubMed  Google Scholar 

  52. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001; 58: 445–452.

    Article  CAS  PubMed  Google Scholar 

  53. Reichenberg A, Kraus T, Haack M, Schuld A, Pollmacher T, Yirmiya R . Endotoxin-induced changes in food consumption in healthy volunteers are associated with TNF-alpha and IL-6 secretion. Psychoneuroendocrinology 2002; 27: 945–956.

    Article  CAS  PubMed  Google Scholar 

  54. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M . Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alpha-2b therapy. J Clin Psychiatry 2003; 64: 708–714.

    Article  PubMed  Google Scholar 

  55. Dieperink E, Ho SB, Tetrick L, Thuras P, Dua K, Willenbring ML . Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psychiatry 2004; 26: 237–240.

    Article  PubMed  Google Scholar 

  56. Bonaccorso S, Meltzer HY, Maes M . Psychological and behavioral effects of interferons. Curr Opin Psychiatrie 2000; 13: 673–677.

    Article  Google Scholar 

  57. Schäfer M, Horn M, Schmidt F, Schmid-Wendtner MH, Volkenandt M, Ackenheil M et al. Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha. Brain Behav Immun 2004; 18: 555–562.

    Article  CAS  Google Scholar 

  58. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 7: 942–947.

    Article  CAS  PubMed  Google Scholar 

  59. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R . Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002; 7: 468–473.

    Article  CAS  PubMed  Google Scholar 

  60. Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D et al. Interferon-alpha-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol Psychiatry 2003; 54: 906–914.

    Article  CAS  PubMed  Google Scholar 

  61. Capuron L, Miller AH . Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 2004; 56: 819–824.

    Article  CAS  PubMed  Google Scholar 

  62. Loftis JM, Hauser P, Macey TA, Lowe JD . Can rodents be used to model interferon-alpha-induced depressive symptoms? Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1364–1365.

    Article  CAS  PubMed  Google Scholar 

  63. Raison CL, Capuron L, Miller AH . Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006; 27: 24–31.

    Article  CAS  PubMed  Google Scholar 

  64. Müller N, Hofschuster E, Ackenheil M, Mempel W, Eckstein R . Investigations of the cellular immunity during depression and the free interval: evidence for an immune activation in affective psychosis. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17: 713–730.

    Article  PubMed  Google Scholar 

  65. Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 1995; 34: 301–309.

    Article  CAS  PubMed  Google Scholar 

  66. Maes M, Meltzer HY, Buckley P, Bosmans E . Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur Arch Psychiatry Clin Neurosci 1995; 244: 325–329.

    Article  CAS  PubMed  Google Scholar 

  67. Irwin M . Immune correlates of depression. Adv Exp Med Biol 1999; 461: 1–24.

    Article  CAS  PubMed  Google Scholar 

  68. Nunes SOV, Reiche EMV, Morimoto HK, Matsuo T, Itano EN, Xavier ECD et al. Immune and hormonal activity in adults suffering from depression. Braz J Med Biol Res 2002; 35: 581–587.

    Article  CAS  PubMed  Google Scholar 

  69. Müller N, Schwarz MJ . Immunology in anxiety and depression. In: Kasper S, den Boer JA, Sitsen JMA (eds). Handbook of Depression and Anxiety. Marcel Dekker: New York, 2002, pp 267–288.

    Google Scholar 

  70. Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M . Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol 2001; 11: 203–208.

    Article  CAS  PubMed  Google Scholar 

  71. Herbert TB, Cohen S . Depression and immunity: a meta-analytic review. Psychol Bull 1993; 113: 472–486.

    Article  CAS  PubMed  Google Scholar 

  72. Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H . Major depressive disorder is associated with elevated monocyte counts. Acta Psychiatr Scand 1996; 94: 198–204.

    Article  CAS  PubMed  Google Scholar 

  73. Rothermundt M, Arolt V, Fenker J, Gutbrodt H, Peters M, Kirchner H . Different immune patterns in melancholic and non-melancholic major depression. Eur Arch Psychiatry Clin Neurosci 2001; 251: 90–97.

    Article  CAS  PubMed  Google Scholar 

  74. Duch DS, Woolf JH, Nichol CA, Davidson JR, Garbutt JC . Urinary excretion of biopterin and neopterin in psychiatric disorders. Psychiatry Res 1984; 11: 83–89.

    Article  CAS  PubMed  Google Scholar 

  75. Dunbar PR, Hill J, Neale TJ, Mellsop GW . Neopterin measurement provides evidence of altered cell-mediated immunity in patients with depression, but not with schizophrenia. Psychol Med 1992; 22: 1051–1057.

    Article  CAS  PubMed  Google Scholar 

  76. Maes M, Scharpe S, Meltzer HY, Okayli G, Bosmans E, D'Hondt P et al. Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res 1994; 54: 143–160.

    Article  CAS  PubMed  Google Scholar 

  77. Bonaccorso S, Lin AH, Verkerk R, Van Hunsel F, Libbrecht I, Scharpe S et al. Immune markers in fibromyalgia: comparison with major depressed patients and normal volunteers. J Affect Disord 1998; 48: 75–82.

    Article  CAS  PubMed  Google Scholar 

  78. Maes M . Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 11–38.

    Article  CAS  PubMed  Google Scholar 

  79. Schiepers OJ, Wichers MC, Maes M . Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 201–217.

    Article  CAS  PubMed  Google Scholar 

  80. Maes M, Scharpe S, Meltzer HY, Bosmans E, Suy E, Calabrese J et al. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic–pituitary–adrenal axis in severe depression. Psychiatry Res 1993; 49: 11–27.

    Article  CAS  PubMed  Google Scholar 

  81. Jun TY, Pae CU, Hoon H, Chae JH, Bahk WM, Kim KS et al. Possible association between G308A tumour necrosis factor-alpha gene polymorphism and major depressive disorder in the Korean population. Psychiatr Genet 2003; 13: 179–181.

    Article  PubMed  Google Scholar 

  82. Fertuzinhos SM, Oliveira JR, Nishimura AL, Pontual D, Carvalho DR, Sougey EB et al. Analysis of IL-1alpha, IL-1beta, and IL-1RA [correction of IL-RA] polymorphisms in dysthymia. J Mol Neurosci 2004; 22: 251–256.

    Article  CAS  PubMed  Google Scholar 

  83. Rosa A, Peralta V, Papiol S, Cuesta MJ, Serrano F, Martinez-Larrea A et al. Interleukin-1beta (IL-1beta) gene and increased risk for the depressive symptom-dimension in schizophrenia spectrum disorders. Am J Med Genet B Neuropsychiatr Genet 2004; 124: 10–14.

    Article  Google Scholar 

  84. Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H . Increased CD56+ natural killer cells and related cytokines in major depression. Clin Immunol Immunopathol 1996; 78: 83–85.

    Article  CAS  PubMed  Google Scholar 

  85. Myint AM, Leonard BE, Steinbusch HW, Kim YK . Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord 2005; 88: 167–173.

    Article  CAS  PubMed  Google Scholar 

  86. Pavon L, Sandoval-Lopez G, Eugenia HM, Loria F, Estrada I, Perez M et al. Th2 cytokine response in major depressive disorder patients before treatment. J Neuroimmunol 2006; 172: 156–165.

    Article  CAS  PubMed  Google Scholar 

  87. Sluzewska A, Rybakowski J, Bosmans E, Sobieska M, Berghmans R, Maes M et al. Indicators of immune activation in major depression. Psychiatry Res 1996; 64: 161–167.

    Article  CAS  PubMed  Google Scholar 

  88. Schlatter J, Ortuno F, Cervera-Enguix S . Lymphocyte subsets and lymphokine production in patients with melancholic versus nonmelancholic depression. Psychiatry Res 2004; 128: 259–265.

    Article  CAS  PubMed  Google Scholar 

  89. Levine J, Barak Y, Chengappa KN, Rapoport A, Rebey M, Barak V . Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 1999; 40: 171–176.

    Article  CAS  PubMed  Google Scholar 

  90. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H . Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000; 22: 370–379.

    Article  CAS  PubMed  Google Scholar 

  91. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E . Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) 2003; 170: 429–433.

    Article  CAS  Google Scholar 

  92. Penninx BW, Kritchevsky SB, Yaffe K, Newman AB, Simonsick EM, Rubin S et al. Inflammatory markers and depressed mood in older persons: results from the health, aging and body composition study. Biol Psychiatry 2003; 54: 566–572.

    Article  CAS  PubMed  Google Scholar 

  93. Fitzgerald P, O'brien SM, Scully P, Rijkers K, Scott LV, Dinan TG . Cutaneous glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant depression. Psychol Med 2006; 36: 37–43.

    Article  PubMed  Google Scholar 

  94. Schlatter J, Ortuno F, Cervera-Enguix S . Differences in interleukins' patterns between dysthymia and major depression. Eur Psychiatry 2001; 16: 317–319.

    Article  CAS  PubMed  Google Scholar 

  95. Owen BM, Eccleston D, Ferrier IN, Young AH . Raised levels of plasma interleukin-1beta in major and postviral depression. Acta Psychiatr Scand 2001; 103: 226–228.

    Article  CAS  PubMed  Google Scholar 

  96. Thomas AJ, Davis S, Morris C, Jackson E, Harrison R, O'Brien JT . Increase in interleukin-1beta in late-life depression. Am J Psychiatry 2005; 162: 175–177.

    Article  PubMed  Google Scholar 

  97. Marques-Deak AH, Neto FL, Dominguez WV, Solis AC, Kurcgant D, Sato F et al. Cytokine profiles in women with different subtypes of major depressive disorder. J Psychiatr Res 2007; 41: 152–159.

    Article  CAS  PubMed  Google Scholar 

  98. Tsao CW, Lin YS, Chen CC, Bai CH, Wu SR . Cytokines and serotonin transporter in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 899–905.

    Article  CAS  PubMed  Google Scholar 

  99. Berk M, Wadee AA, Kuschke RH, O'Neill KA . Acute phase proteins in major depression. J Psychosom Res 1997; 43: 529–534.

    Article  CAS  PubMed  Google Scholar 

  100. Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H . Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997; 9: 853–858.

    Article  CAS  PubMed  Google Scholar 

  101. Frommberger UH, Bauer J, Haselbauer P, Fraulin A, Riemann D, Berger M . Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 1997; 247: 228–233.

    Article  CAS  PubMed  Google Scholar 

  102. Song C, Lin A, Bonaccorso S, Heide C, Verkerk R, Kenis G et al. The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J Affect Disord 1998; 49: 211–219.

    Article  CAS  PubMed  Google Scholar 

  103. Trzonkowski P, Mysliwska J, Godlewska B, Szmit E, Lukaszuk K, Wieckiewicz J et al. Immune consequences of the spontaneous pro-inflammatory status in depressed elderly patients. Brain Behav Immun 2004; 18: 135–148.

    Article  CAS  PubMed  Google Scholar 

  104. Pike JL, Irwin MR . Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder. Brain Behav Immun 2006; 20: 169–174.

    Article  CAS  PubMed  Google Scholar 

  105. Alesci S, Martinez PE, Kelkar S, Ilias I, Ronsaville DS, Listwak SJ et al. Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. J Clin Endocrinol Metab 2005; 90: 2522–2530.

    Article  CAS  PubMed  Google Scholar 

  106. Musselman DL, Miller AH, Porter MR, Manatunga A, Gao F, Penna S et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 2001; 158: 1252–1257.

    Article  CAS  PubMed  Google Scholar 

  107. Katila H, Appelberg B, Hurme M, Rimon R . Plasma levels of interleukin-1 beta and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophr Res 1994; 12: 29–34.

    Article  CAS  PubMed  Google Scholar 

  108. Brambilla F, Maggioni M . Blood levels of cytokines in elderly patients with major depressive disorder. Acta Psychiatr Scand 1998; 97: 309–313.

    Article  CAS  PubMed  Google Scholar 

  109. Kagaya A, Kugaya A, Takebayashi M, Fukue-Saeki M, Saeki T, Yamawaki S et al. Plasma concentrations of interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressed patients in Japan. Neuropsychobiology 2001; 43: 59–62.

    Article  CAS  PubMed  Google Scholar 

  110. Haack M, Hinze SD, Fenzel T, Kraus T, Kuhn M, Schuld A et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 1999; 33: 407–418.

    Article  CAS  PubMed  Google Scholar 

  111. Ershler WB, Sun WH, Binkley N, Gravenstein S, Volk MJ, Kamoske G et al. Interleukin-6 and aging: blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction. Lymphokine Cytokine Res 1993; 12: 225–230.

    CAS  PubMed  Google Scholar 

  112. Stübner S, Schon T, Padberg F, Teipel SJ, Schwarz MJ, Haslinger A et al. Interleukin-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: no alteration of soluble gp130. Neurosci Lett 1999; 259: 145–148.

    Article  PubMed  Google Scholar 

  113. Carpenter LL, Heninger GR, Malison RT, Tyrka AR, Price LH . Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression. J Affect Disord 2004; 79: 285–289.

    Article  CAS  PubMed  Google Scholar 

  114. Romanovsky AA, Almeida MC, Aronoff DM, Ivanov AI, Konsman JP, Steiner AA et al. Fever and hypothermia in systemic inflammation: recent discoveries and revisions. Front Biosci 2005; 10: 2193–2216.

    Article  CAS  PubMed  Google Scholar 

  115. Mendlovic S, Mozes E, Eilat E, Doron A, Lereya J, Zakuth V et al. Immune activation in non-treated suicidal major depression. Immunol Lett 1999; 67: 105–108.

    Article  CAS  PubMed  Google Scholar 

  116. Penttinen J . Hypothesis: low serum cholesterol, suicide, and interleukin-2. Am J Epidemiol 1995; 141: 716–718.

    Article  CAS  PubMed  Google Scholar 

  117. Nassberger L, Traskman-Bendz L . Increased soluble interleukin-2 receptor concentrations in suicide attempters. Acta Psychiatr Scand 1993; 88: 48–52.

    Article  CAS  PubMed  Google Scholar 

  118. Baron DA, Hardie T, Baron SH . Possible association of interleukin-2 treatment with depression and suicide. J Am Osteopath Assoc 1993; 93: 799–800.

    Article  CAS  PubMed  Google Scholar 

  119. Kaestner F, Hettich M, Peters M, Sibrowski W, Hetzel G, Ponath G et al. Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity. J Affect Disord 2005; 87: 305–311.

    Article  CAS  PubMed  Google Scholar 

  120. Lesperance F, Frasure-Smith N, Theroux P, Irwin M . The association between major depression and levels of soluble intercellular adhesion molecule 1, interleukin-6, and C-reactive protein in patients with recent acute coronary syndromes. Am J Psychiatry 2004; 161: 271–277.

    Article  PubMed  Google Scholar 

  121. Thomas AJ, Ferrier IN, Kalaria RN, Woodward SA, Ballard C, Oakley A et al. Elevation in late-life depression of intercellular adhesion molecule-1 expression in the dorsolateral prefrontal cortex. Am J Psychiatry 2000; 157: 1682–1684.

    Article  CAS  PubMed  Google Scholar 

  122. Rieckmann P, Nunke K, Burchhardt M, Albrecht M, Wiltfang J, Ulrich M et al. Soluble intercellular adhesion molecule-1 in cerebrospinal fluid: an indicator for the inflammatory impairment of the blood–cerebrospinal fluid barrier. J Neuroimmunol 1993; 47: 133–140.

    Article  CAS  PubMed  Google Scholar 

  123. Lane JH, Sasseville VG, Smith MO, Vogel P, Pauley DR, Heyes MP et al. Neuroinvasion by simian immunodeficiency virus coincides with increased numbers of perivascular macrophages/microglia and intrathecal immune activation. J Neurovirol 1996; 2: 423–432.

    Article  CAS  PubMed  Google Scholar 

  124. Marzi M, Vigano A, Trabattoni D, Villa ML, Salvaggio A, Clerici E et al. Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clin Exp Immunol 1996; 106: 127–133.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. Saito S, Sakai M, Sasaki Y, Tanebe K, Tsuda H, Michimata T . Quantitative analysis of peripheral blood Th0, Th1, Th2 and the Th1:Th2 cell ratio during normal human pregnancy and preeclampsia. Clin Exp Immunol 1999; 117: 550–555.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Maes M, Verkerk R, Bonaccorso S, Ombelet W, Bosmans E, Scharpe S . Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. Life Sci 2002; 71: 1837–1848.

    Article  CAS  PubMed  Google Scholar 

  127. Ostensen M, Forger F, Nelson JL, Schuhmacher A, Hebisch G, Villiger PM . Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post partum. Ann Rheum Dis 2005; 64: 839–844.

    Article  CAS  PubMed  Google Scholar 

  128. Stein GS . The pattern of mental change and body weight change in the first post-partum week. J Psychosom Res 1980; 24: 165–171.

    Article  CAS  PubMed  Google Scholar 

  129. Josefsson A, Berg G, Nordin C, Sydsjo G . Prevalence of depressive symptoms in late pregnancy and postpartum. Acta Obstet Gynecol Scand 2001; 80: 251–255.

    Article  CAS  PubMed  Google Scholar 

  130. O'Hara MW, Swain AM . Rates and risk of post-partum depression – a meta-analysis. In Rev Psychiatry 1996; 8: 37–54.

    Article  Google Scholar 

  131. Kohl C, Walch T, Huber R, Kemmler G, Neurauter G, Fuchs D et al. Measurement of tryptophan, kynurenine and neopterin in women with and without postpartum blues. J Affect Disord 2005; 86: 135–142.

    Article  CAS  PubMed  Google Scholar 

  132. Gard PR, Handley SL, Parsons AD, Waldron G . A multivariate investigation of postpartum mood disturbance. Br J Psychiatry 1986; 148: 567–575.

    Article  CAS  PubMed  Google Scholar 

  133. Abou-Saleh MT, Ghubash R, Karim L, Krymski M, Anderson DN . The role of pterins and related factors in the biology of early postpartum depression. Eur Neuropsychopharmacol 1999; 9: 295–300.

    CAS  PubMed  Google Scholar 

  134. Linnoila M, Whorton AR, Rubinow DR, Cowdry RW, Ninan PT, Waters RN . CSF prostaglandin levels in depressed and schizophrenic patients. Arch Gen Psychiatry 1983; 40: 405–406.

    Article  CAS  PubMed  Google Scholar 

  135. Calabrese JR, Skwerer RG, Barna B, Gulledge AD, Valenzuela R, Butkus A et al. Depression, immunocompetence, and prostaglandins of the E series. Psychiatry Res 1986; 17: 41–47.

    Article  CAS  PubMed  Google Scholar 

  136. Ohishi K, Ueno R, Nishino S, Sakai T, Hayaishi O . Increased level of salivary prostaglandins in patients with major depression. Biol Psychiatry 1988; 23: 326–334.

    Article  CAS  PubMed  Google Scholar 

  137. Mtabaji JP, Manku MS, Horrobin DF . Actions of the tricyclic antidepressant clomipramine on responses to pressor agents. Interactions with prostaglandin E2. Prostaglandins 1977; 14: 125–132.

    Article  CAS  PubMed  Google Scholar 

  138. Yaron I, Shirazi I, Judovich R, Levartovsky D, Caspi D, Yaron M . Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum 1999; 42: 2561–2568.

    Article  CAS  PubMed  Google Scholar 

  139. Paykel ES, Myers JK, Dienelt MN, Klerman GL, Lindenthal JJ, Pepper MP . Life events and depression. A controlled study. Arch Gen Psychiatry 1969; 21: 753–760.

    Article  CAS  PubMed  Google Scholar 

  140. Hasler G, Drevets WC, Manji HK, Charney DS . Discovering endophenotypes for major depression. Neuropsychopharmacology 2004; 29: 1765–1781.

    Article  CAS  PubMed  Google Scholar 

  141. Roy A, Pickar D, Paul S, Doran A, Chrousos GP, Gold PW . CSF corticotropin-releasing hormone in depressed patients and normal control subjects. Am J Psychiatry 1987; 144: 641–645.

    Article  CAS  PubMed  Google Scholar 

  142. Burke HM, Davis MC, Otte C, Mohr DC . Depression and cortisol responses to psychological stress: a meta-analysis. Psychoneuroendocrinology 2005; 30: 846–856.

    Article  CAS  PubMed  Google Scholar 

  143. Besedovsky H, del Rey A, Sorkin E, Dinarello CA . Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 1986; 233: 652–654.

    Article  CAS  PubMed  Google Scholar 

  144. Berkenbosch F, van Oers J, del Rey A, Tilders F, Besedovsky H . Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1. Science 1987; 238: 524–526.

    Article  CAS  PubMed  Google Scholar 

  145. Sundar SK, Cierpial MA, Kilts C, Ritchie JC, Weiss JM . Brain IL-1-induced immunosuppression occurs through activation of both pituitary–adrenal axis and sympathetic nervous system by corticotropin-releasing factor. J Neurosci 1990; 10: 3701–3706.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Weiss JM, Quan N, Sundar SK . Immunological consequences of interleukin-1 in the brain. Neuropsychopharmacology 1994; 10: 833.

    Google Scholar 

  147. Plata-Salaman CR . Immunoregulators in the nervous system. Neurosci Biobehav Rev 1991; 15: 185–215.

    Article  CAS  PubMed  Google Scholar 

  148. Wang X, Wu H, Miller AH . Interleukin 1alpha (IL-1alpha) induced activation of p38 mitogen-activated protein kinase inhibits glucocorticoid receptor function. Mol Psychiatry 2004; 9: 65–75.

    Article  CAS  PubMed  Google Scholar 

  149. Salas MA, Evans SW, Levell MJ, Whicher JT . Interleukin-6 and ACTH act synergistically to stimulate the release of corticosterone from adrenal gland cells. Clin Exp Immunol 1990; 79: 470–473.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  150. Zhou D, Kusnecov AW, Shurin MR, DePaoli M, Rabin BS . Exposure to physical and psychological stressors elevates plasma interleukin 6: relationship to the activation of hypothalamic–pituitary–adrenal axis. Endocrinology 1993; 133: 2523–2530.

    Article  CAS  PubMed  Google Scholar 

  151. Miyahara S, Komori T, Fujiwara R, Shizuya K, Yamamoto M, Ohmori M et al. Effects of repeated stress on expression of interleukin-6 (IL-6) and IL-6 receptor mRNAs in rat hypothalamus and midbrain. Life Sci 2000; 66: L93–L98.

    Article  Google Scholar 

  152. Green AR, Sourkes TL, Young SN . Liver and brain tryptophan metabolism following hydrocortisone administration to rats and gerbils. Br J Pharmacol 1975; 53: 287–292.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  153. O'brien SM, Scott LV, Dinan TG . Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol 2004; 19: 397–403.

    Article  CAS  PubMed  Google Scholar 

  154. Czeh B, Simon M, Schmelting B, Hiemke C, Fuchs E . Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment. Neuropsychopharmacology 2006; 31: 1616–1626.

    Article  CAS  PubMed  Google Scholar 

  155. Pugh CR, Nguyen KT, Gonyea JL, Fleshner M, Wakins LR, Maier SF et al. Role of interleukin-1 beta in impairment of contextual fear conditioning caused by social isolation. Behav Brain Res 1999; 106: 109–118.

    Article  CAS  PubMed  Google Scholar 

  156. Nguyen KT, Deak T, Owens SM, Kohno T, Fleshner M, Watkins LR et al. Exposure to acute stress induces brain interleukin-1beta protein in the rat. J Neurosci 1998; 18: 2239–2246.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  157. Bacher M, Meinhardt A, Lan HY, Dhabhar FS, Mu W, Metz CN et al. MIF expression in the rat brain: implications for neuronal function. Mol Med 1998; 4: 217–230.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  158. Niino M, Ogata A, Kikuchi S, Tashiro K, Nishihira J . Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behcet's disease. J Neurol Sci 2000; 179: 127–131.

    Article  CAS  PubMed  Google Scholar 

  159. Suzuki T, Ogata A, Tashiro K, Nagashima K, Tamura M, Yasui K et al. Japanese encephalitis virus up-regulates expression of macrophage migration inhibitory factor (MIF) mRNA in the mouse brain. Biochim Biophys Acta 2000; 1517: 100–106.

    Article  CAS  PubMed  Google Scholar 

  160. Madrigal JL, Garcia-Bueno B, Moro MA, Lizasoain I, Lorenzo P, Leza JC . Relationship between cyclooxygenase-2 and nitric oxide synthase-2 in rat cortex after stress. Eur J Neurosci 2003; 18: 1701–1705.

    Article  PubMed  Google Scholar 

  161. Sapolsky RM . A mechanism for glucocorticoid toxicity in the hippocampus: increased neuronal vulnerability to metabolic insults. J Neurosci 1985; 5: 1228–1232.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  162. Woolley CS, Gould E, McEwen BS . Exposure to excess glucocorticoids alters dendritic morphology of adult hippocampal pyramidal neurons. Brain Res 1990; 531: 225–231.

    Article  CAS  PubMed  Google Scholar 

  163. Moghaddam B, Bolinao ML, Stein-Behrens B, Sapolsky R . Glucocorticoids mediate the stress-induced extracellular accumulation of glutamate. Brain Res 1994; 655: 251–254.

    Article  CAS  PubMed  Google Scholar 

  164. Stein-Behrens BA, Lin WJ, Sapolsky RM . Physiological elevations of glucocorticoids potentiate glutamate accumulation in the hippocampus. J Neurochem 1994; 63: 596–602.

    Article  CAS  PubMed  Google Scholar 

  165. Takahashi T, Kimoto T, Tanabe N, Hattori TA, Yasumatsu N, Kawato S . Corticosterone acutely prolonged N-methyl-D-aspartate receptor-mediated Ca2+ elevation in cultured rat hippocampal neurons. J Neurochem 2002; 83: 1441–1451.

    Article  CAS  PubMed  Google Scholar 

  166. Nair A, Bonneau RH . Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation. J Neuroimmunol 2006; 171: 72–85.

    Article  CAS  PubMed  Google Scholar 

  167. Müller N, Schwarz MJ . Role of the cytokine network in major psychoses. In: Hertz L (ed). Non-Neuronal Cells of the Nervous System: Function and Dysfunction. Elsevier: Amsterdam, 2003, pp 999–1031.

    Chapter  Google Scholar 

  168. Xiao BG, Link H . Is there a balance between microglia and astrocytes in regulating Th1/Th2-cell responses and neuropathologies? Immunol Today 1999; 20: 477–479.

    Article  CAS  PubMed  Google Scholar 

  169. Aloisi F, Ria F, Adorini L . Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. Immunol Today 2000; 21: 141–147.

    Article  CAS  PubMed  Google Scholar 

  170. Cotter D, Pariante C, Rajkowska G . Glial pathology in major psychiatric disorders. In: Agam G, Belmaker RH, Everall I (eds). The Post-Mortem Brain in Psychiatric Research. Kluwer Acadamic Publication: Boston, 2002, pp 291–324.

    Google Scholar 

  171. Ongur D, Drevets WC, Price JL . Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 1998; 95: 13290–13295.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  172. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999; 45: 1085–1098.

    Article  CAS  PubMed  Google Scholar 

  173. Rajkowska G, Halaris A, Selemon LD . Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry 2001; 49: 741–752.

    Article  CAS  PubMed  Google Scholar 

  174. Rajkowska G . Depression: what we can learn from postmortem studies. Neuroscientist 2003; 9: 273–284.

    Article  PubMed  Google Scholar 

  175. Johnston-Wilson NL, Sims CD, Hofmann J-P, Anderson L, Shore AD, Torrey EF et al. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. Mol Psychiatry 2000; 5: 142–149.

    Article  CAS  PubMed  Google Scholar 

  176. Miguel-Hidalgo JJ, Baucom C, Dilley G, Overholser JC, Meltzer HY, Stockmeier CA et al. Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. Biol Psychiatry 2000; 48: 861–873.

    Article  CAS  PubMed  Google Scholar 

  177. Si X, Miguel-Hidalgo JJ, O'Dwyer G, Stockmeier CA, Rajkowska G . Age-dependent reductions in the level of glial fibrillary acidic protein in the prefrontal cortex in major depression. Neuropsychopharmacology 2004; 29: 2088–2096.

    Article  CAS  PubMed  Google Scholar 

  178. Davis S, Thomas A, Perry R, Oakley A, Kalaria RN, O'Brien JT . Glial fibrillary acidic protein in late life major depressive disorder: an immunocytochemical study. J Neurol Neurosurg Psychiatry 2002; 73: 556–560.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  179. Fatemi SH, Laurence JA, raghi-Niknam M, Stary JM, Schulz SC, Lee S et al. Glial fibrillary acidic protein is reduced in cerebellum of subjects with major depression, but not schizophrenia. Schizophr Res 2004; 69: 317–323.

    Article  PubMed  Google Scholar 

  180. Rajkowska G . Astroglia in the cortex of schizophrenics: histopathology finding. World J Biol Psychiatry 2005; 6: 74.

    Google Scholar 

  181. Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA 2005; 102: 15653–15658.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  182. Gegelashvili G, Robinson MB, Trotti D, Rauen T . Regulation of glutamate transporters in health and disease. Prog Brain Res 2001; 132: 267–286.

    Article  CAS  PubMed  Google Scholar 

  183. Auger C, Attwell D . Fast removal of synaptic glutamate by postsynaptic transporters. Neuron 2000; 28: 547–558.

    Article  CAS  PubMed  Google Scholar 

  184. Danbolt NC . Glutamate uptake. Prog Neurobiol 2001; 65: 1–105.

    Article  CAS  PubMed  Google Scholar 

  185. Thomas K . Immunomodulation in Mice Induced by the Antidepressant Drug Zimeldine. Thesis, University of Utrecht: Utrecht, 1989.

    Google Scholar 

  186. Bengtsson BO, Zhu J, Thorell LH, Olsson T, Link H, Walinder J . Effects of zimeldine and its metabolites, clomipramine, imipramine and maprotiline in experimental allergic neuritis in Lewis rats. J Neuroimmunol 1992; 39: 109–122.

    Article  CAS  PubMed  Google Scholar 

  187. Song C, Leonard BE . An acute phase protein response in the olfactory bulbectomised rat: effect of sertraline treatment. Med Sci Res 1994; 22: 313–314.

    CAS  Google Scholar 

  188. Zhu J, Bengtsson BO, Mix E, Thorell LH, Olsson T, Link H . Effect of monoamine reuptake inhibiting antidepressants on major histocompatibility complex expression on macrophages in normal rats and rats with experimental allergic neuritis (EAN). Immunopharmacology 1994; 27: 225–244.

    Article  CAS  PubMed  Google Scholar 

  189. Leonard BE . The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 767–780.

    Article  CAS  PubMed  Google Scholar 

  190. Maes M, Song C, Lin AH, Bonaccorso S, Kenis G, De Jongh R et al. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology 1999; 20: 370–379.

    Article  CAS  PubMed  Google Scholar 

  191. Kubera M, Lin AH, Kenis G, Bosmans E, van BD, Maes M . Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol 2001; 21: 199–206.

    Article  CAS  PubMed  Google Scholar 

  192. Szuster-Ciesielska A, Tustanowska-Stachura A, Slotwinska M, Marmurowska-Michalowska H, Kandefer-Szerszen M . In vitro immunoregulatory effects of antidepressants in healthy volunteers. Pol J Pharmacol 2003; 55: 353–362.

    Article  CAS  PubMed  Google Scholar 

  193. Mohr DC, Goodkin DE, Islar J, Hauser SL, Genain CP . Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis. Arch Neurol 2001; 58: 1081–1086.

    Article  CAS  PubMed  Google Scholar 

  194. Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H . Cytokine production and serum proteins in depression. Scand J Immunol 1995; 41: 534–538.

    Article  CAS  PubMed  Google Scholar 

  195. Kenis G, Maes M . Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacology 2002; 5: 401–412.

    Article  CAS  Google Scholar 

  196. Obuchowicz E, Kowalski J, Labuzek K, Krysiak R, Pendzich J, Herman ZS . Amitriptyline and nortriptyline inhibit interleukin-1 release by rat mixed glial and microglial cell cultures. Int J Neuropsychopharmacology 2006; 9: 27–35.

    Article  CAS  Google Scholar 

  197. Sluzewska A, Rybakowski JK, Laciak M, Mackiewicz A, Sobieska M, Wiktorowicz K . Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann NY Acad Sci 1995; 762: 474–476.

    Article  CAS  PubMed  Google Scholar 

  198. Basterzi AD, Aydemir C, Kisa C, Aksaray S, Tuzer V, Yazici K et al. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum Psychopharmacol 2005; 20: 473–476.

    Article  CAS  PubMed  Google Scholar 

  199. Narita K, Murata T, Takahashi T, Kosaka H, Omata N, Wada Y . Plasma levels of adiponectin and tumor necrosis factor-alpha in patients with remitted major depression receiving long-term maintenance antidepressant therapy. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1159–1162.

    Article  CAS  PubMed  Google Scholar 

  200. Pollak Y, Yirmiya R . Cytokine-induced changes in mood and behaviour: implications for ‘depression due to a general medical condition’, immunotherapy and antidepressive treatment. Int J Neuropsychopharmacology 2002; 5: 389–399.

    Article  CAS  Google Scholar 

  201. Hestad KA, Tonseth S, Stoen CD, Ueland T, Aukrust P . Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J ECT 2003; 19: 183–188.

    Article  PubMed  Google Scholar 

  202. Dimitrov S, Lange T, Tieken S, Fehm HL, Born J . Sleep associated regulation of T helper 1/T helper 2 cytokine balance in humans. Brain Behav Immun 2004; 18: 341–348.

    Article  CAS  PubMed  Google Scholar 

  203. Casolini P, Catalani A, Zuena AR, Angelucci L . Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J Neurosci Res 2002; 68: 337–343.

    Article  CAS  PubMed  Google Scholar 

  204. Hu F, Wang X, Pace TW, Wu H, Miller AH . Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function. Mol Psychiatry 2005; 10: 426–428.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  205. Song C, Leonard BE . Fundamentals of Psychoneuroimmunology. John Wiley and Sons: Chichester, New York, 2000.

    Google Scholar 

  206. Cao C, Matsumura K, Ozaki M, Watanabe Y . Lipopolysaccharide injected into the cerebral ventricle evokes fever through induction of cyclooxygenase-2 in brain endothelial cells. J Neurosci 1999; 19: 716–725.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  207. Sandrini M, Vitale G, Pini LA . Effect of rofecoxib on nociception and the serotonin system in the rat brain. Inflamm Res 2002; 51: 154–159.

    Article  CAS  PubMed  Google Scholar 

  208. De La GR, Asnis GM . The non-steroidal anti-inflammatory drug diclofenac sodium attenuates IFN-alpha induced alterations to monoamine turnover in prefrontal cortex and hippocampus. Brain Res 2003; 977: 70–79.

    Article  CAS  Google Scholar 

  209. Cassano P, Hidalgo A, Burgos V, Adris S, Argibay P . Hippocampal upregulation of the cyclooxygenase-2 gene following neonatal clomipramine treatment (a model of depression). Pharmacogenomics J 2006; 6: 381–387.

    Article  CAS  PubMed  Google Scholar 

  210. Salzberg-Brenhouse HC, Chen EY, Emerich DF, Baldwin S, Hogeland K, Ranelli S et al. Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegeneration. J Pharmacol Exp Ther 2003; 306: 218–228.

    Article  CAS  PubMed  Google Scholar 

  211. Collantes-Esteves E, Fernandez-Perrez CH . Improved self-control of ostheoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. Curr Med Res Opin 2003; 19: 402–410.

    Article  CAS  Google Scholar 

  212. Müller N, Schwarz MJ, Dehning S, Douhet A, Cerovecki A, Goldstein-Müller B et al. The cyclo-oxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006; 11: 680–684.

    Article  PubMed  CAS  Google Scholar 

  213. Hewett SJ, Uliasz TF, Vidwans AS, Hewett JA . Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. J Pharmacol Exp Ther 2000; 293: 417–425.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to N Müller.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Müller, N., Schwarz, M. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 12, 988–1000 (2007). https://doi.org/10.1038/sj.mp.4002006

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.mp.4002006

Keywords

This article is cited by

Search

Quick links